WO2022145465A1 - 新規ガイド核酸機構による遺伝子機能制御 - Google Patents
新規ガイド核酸機構による遺伝子機能制御 Download PDFInfo
- Publication number
- WO2022145465A1 WO2022145465A1 PCT/JP2021/048908 JP2021048908W WO2022145465A1 WO 2022145465 A1 WO2022145465 A1 WO 2022145465A1 JP 2021048908 W JP2021048908 W JP 2021048908W WO 2022145465 A1 WO2022145465 A1 WO 2022145465A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complex
- argonaute
- argonaute protein
- sequence
- guide rna
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 120
- 150000007523 nucleic acids Chemical class 0.000 title description 55
- 102000039446 nucleic acids Human genes 0.000 title description 42
- 108020004707 nucleic acids Proteins 0.000 title description 42
- 230000007246 mechanism Effects 0.000 title description 4
- 108020004414 DNA Proteins 0.000 claims abstract description 258
- 102000008682 Argonaute Proteins Human genes 0.000 claims abstract description 174
- 108010088141 Argonaute Proteins Proteins 0.000 claims abstract description 174
- 102000053602 DNA Human genes 0.000 claims abstract description 123
- 238000000034 method Methods 0.000 claims abstract description 102
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 98
- 230000009471 action Effects 0.000 claims abstract description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 89
- 230000014509 gene expression Effects 0.000 claims description 65
- 230000000694 effects Effects 0.000 claims description 44
- 230000008685 targeting Effects 0.000 claims description 38
- 230000027455 binding Effects 0.000 claims description 35
- 241000894006 Bacteria Species 0.000 claims description 27
- 238000000338 in vitro Methods 0.000 claims description 27
- 230000004048 modification Effects 0.000 claims description 17
- 238000012986 modification Methods 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 14
- 230000001105 regulatory effect Effects 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 230000001276 controlling effect Effects 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 230000014493 regulation of gene expression Effects 0.000 claims description 4
- 238000002715 modification method Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 72
- 235000018102 proteins Nutrition 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 42
- 230000006870 function Effects 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 25
- 239000002609 medium Substances 0.000 description 24
- 108091023037 Aptamer Proteins 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 15
- 239000011535 reaction buffer Substances 0.000 description 15
- 238000012258 culturing Methods 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000238631 Hexapoda Species 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 238000010362 genome editing Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 108091033409 CRISPR Proteins 0.000 description 6
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 235000011147 magnesium chloride Nutrition 0.000 description 6
- 229920002401 polyacrylamide Polymers 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 5
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000009918 complex formation Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 108091032955 Bacterial small RNA Proteins 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 3
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 3
- 235000001535 Ribes X utile Nutrition 0.000 description 3
- 235000016919 Ribes petraeum Nutrition 0.000 description 3
- 244000281247 Ribes rubrum Species 0.000 description 3
- 235000002355 Ribes spicatum Nutrition 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000409811 Bombyx mori nucleopolyhedrovirus Species 0.000 description 2
- 241000589173 Bradyrhizobium Species 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000616340 Calothrix desertica PCC 7102 Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000880396 Dehalococcoides Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 2
- 241001177659 Elusimicrobia bacterium RBG_16_66_12 Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000970829 Mesorhizobium Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241001642886 Planctomycetes bacterium Species 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 108091008103 RNA aptamers Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241000111724 Thermotoga profunda Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000041194 Ago family Human genes 0.000 description 1
- 108091061188 Ago family Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 101100007857 Bacillus subtilis (strain 168) cspB gene Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108020001738 DNA Glycosylase Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 102000028381 DNA glycosylase Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000008157 Histone Demethylases Human genes 0.000 description 1
- 108010074870 Histone Demethylases Proteins 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000555303 Mamestra brassicae Species 0.000 description 1
- 241000321600 Marinitoga Species 0.000 description 1
- 241001357706 Marinitoga piezophila Species 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 210000004460 N cell Anatomy 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000016187 PAZ domains Human genes 0.000 description 1
- 108050004670 PAZ domains Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000052376 Piwi domains Human genes 0.000 description 1
- 108700038049 Piwi domains Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000769980 Rhodobacter sphaeroides ATCC 17025 Species 0.000 description 1
- 229910003797 SPO1 Inorganic materials 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 101100150136 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPO1 gene Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 108010018628 Ulp1 protease Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 101150110403 cspA gene Proteins 0.000 description 1
- 101150068339 cspLA gene Proteins 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000006451 grace's insect medium Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000006870 ms-medium Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present disclosure relates to a site-specific modification method of a DNA molecule that enables manipulation of gene function.
- the CRISPR system possessed by bacteria and archaea has attracted attention as a DNA sequence recognition mechanism using guide nucleic acids, and has been applied as a genome editing technology.
- the CRISPR system utilizes small RNAs (guide RNAs) that are complementary to DNA sequences that invade bacteria to facilitate targeting and degradation of targeted foreign DNA.
- Argonaute proteins derived from bacteria can recognize DNA sequences using guide RNA.
- This Argonaute protein is a guide RNA-dependent RNA target molecule responsible for RNAi in eukaryotes, and the present disclosure utilizes this Argonaute protein as a novel genome editing mechanism and is a site of a DNA molecule that enables manipulation of gene function. A specific modification method is provided.
- the present disclosure provides: (Item 1) It is a method for manipulating gene function by acting site-specifically on a target DNA molecule. A step of providing a complex containing an Argonaute protein, a guide RNA, and an additional sequence, and A method comprising contacting a target DNA molecule with the complex, wherein the guide RNA is designed to direct the complex to a region of the target DNA molecule containing a site of interest. (Item 2) The method according to the above item, wherein the Argonaute protein has an activity of targeting DNA. (Item 3) The method according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item 4) The method according to any one of the above items, wherein the Argonaute protein is derived from a prokaryote.
- (Item 5) The method according to any one of the above items, wherein the Argonaute protein is derived from a bacterium.
- (Item 6) The method according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item 7) The method according to any one of the above items, wherein the complex is formed in vitro.
- (Item 8) The method according to any one of the above items, wherein the complex is formed in vitro and the target DNA molecule is present in vivo.
- (Item A1) A method for regulating the expression of a target DNA molecule, A step of providing a complex containing an Argonaute protein, a guide RNA, and an additional sequence, and The step of dissociating at least a part of the double-stranded DNA sequence in the target DNA molecule, The guide RNA comprises contacting the complex with at least a partially dissociated double-stranded DNA sequence, the guide RNA in a region containing the double-stranded DNA sequence at least partially dissociated.
- a method designed to guide (Item A2) The method according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA.
- (Item A3) The method according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item A4) The method according to any one of the above items, wherein the Argonaute protein is derived from a prokaryote.
- (Item A5) The method according to any one of the above items, wherein the Argonaute protein is derived from a bacterium.
- the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item A7) The method according to any one of the above items, wherein the complex is formed in vitro.
- (Item A8) The method according to any one of the above items, wherein the complex is formed in vitro and the target DNA molecule is present in vivo.
- (Item B1) Argonaute-guide RNA complex, Argonaute protein and A guide RNA complex comprising a synthesized guide RNA polynucleotide, wherein the guide sequence is designed such that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence.
- (Item B2) The complex according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA.
- (Item B3) The complex according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item B4) The complex according to any one of the above items, wherein the Argonaute protein is derived from a prokaryote.
- (Item B5) The complex according to any one of the above items, wherein the Argonaute protein is derived from a bacterium.
- (Item B6) The complex according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item C1) An Argonaute-guide RNA complex for site-specific action of target DNA molecules to manipulate gene function.
- the guide sequence is designed such that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence, and the complex is directed to the target molecule.
- An Argonaute-guide RNA complex that acts site-specificly on the target DNA molecule by binding to manipulate gene function.
- (Item C4) The complex according to any one of the above items, wherein the Argonaute protein is derived from a prokaryote.
- (Item C5) The complex according to any one of the above items, wherein the Argonaute protein is derived from a bacterium.
- (Item C6) The complex according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- the complex according to any one of the above items, wherein the manipulation of the gene function comprises controlling gene expression, modifying the gene sequence, and / or both.
- (Item C8) The complex according to any one of the above items, wherein the manipulation of the gene function comprises regulation of gene expression.
- (Item C9) The complex according to any one of the above items, wherein the manipulation of the gene function comprises a gene sequence modification.
- (Item D1) An Argonaute-guide RNA complex for regulating the expression of target DNA molecules. Argonaute protein and Including the synthesized guide RNA polynucleotide, the guide sequence is designed such that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence, and the complex is directed to the target molecule. An Argonaute-guide RNA complex whose expression of the target DNA molecule is regulated by binding.
- (Item D2) The complex according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA.
- (Item D3) The complex according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item D4) The complex according to any one of the above items, wherein the Argonaute protein is derived from a prokaryote.
- (Item D5) The complex according to any one of the above items, wherein the Argonaute protein is derived from a bacterium.
- the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item E1) A system or kit for manipulating gene function by acting site-specifically on a target DNA molecule.
- a system or kit comprising a target DNA molecule with means or reagents for contacting the complex and the guide RNA being designed to direct the complex to a region of interest in the target DNA molecule. ..
- the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- the system or kit according to any one of the above items, wherein the Argonaute protein is of prokaryotic origin.
- (Item E5) The system or kit according to any one of the above items, wherein the Argonaute protein is of bacterial origin.
- (Item E6) The system or kit according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item E7) The system or kit according to any one of the above items, comprising means for forming the complex in vitro.
- (Item F1) A system or kit for regulating the expression of a target DNA molecule, With two or more complexes, including Argonaute proteins, guide RNAs and additional sequences, or two or more of them.
- the double-stranded DNA sequence, which is at least partially dissociated comprises means or reagents for contacting the complex, and the guide RNA comprises the complex, which is at least partially dissociated.
- a system or kit designed to guide you to the area. (Item F2) The system or kit according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA.
- (Item F3) The system or kit according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item F4) The system or kit according to any one of the above items, wherein the Argonaute protein is of prokaryotic origin.
- (Item F5) The system or kit according to any one of the above items, wherein the Argonaute protein is of bacterial origin.
- (Item F6) The system or kit according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item F7) The system or kit according to any one of the above items, further comprising means for forming the complex in vitro.
- (Item F8) The system or kit according to any one of the above items, further comprising means for forming the complex in vitro, wherein the target DNA molecule is present in vivo.
- (Item G1) The use of an Argonaute-guide RNA complex for site-specific action of a target DNA molecule to manipulate gene function, wherein the Argonaute-guide RNA complex is used.
- Argonaute protein and Including the synthesized guide RNA polynucleotide, the guide sequence is designed such that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence, and the complex is directed to the target molecule.
- Use where binding acts site-specificly on the target DNA molecule to manipulate gene function.
- (Item G2) The use according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA.
- (Item G3) The use according to any one of the above items, wherein the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- (Item G4) The use according to any one of the above items, wherein the Argonaute protein is of prokaryotic origin.
- (Item G5) The use according to any one of the above items, wherein the Argonaute protein is of bacterial origin.
- (Item G6) The use according to any one of the above items, wherein the Argonaute protein is RsAgo derived from Rhodobactor.
- (Item G7) The use according to any one of the above items, wherein the manipulation of the gene function comprises controlling gene expression, modifying the gene sequence, and / or both.
- (Item G8) The compound use according to any one of the above items, wherein the manipulation of the gene function includes the regulation of gene expression.
- (Item G9) The use according to any one of the above items, wherein the manipulation of the gene function comprises a gene sequence modification.
- (Item H1) The use of an Argonaute-guide RNA complex to regulate the expression of a target DNA molecule, wherein the Argonaute-guide RNA complex is used.
- the guide sequence is designed such that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence, and the complex is directed to the target molecule.
- Use where binding regulates the expression of the target DNA molecule.
- the Argonaute protein has an activity of targeting DNA.
- the Argonaute protein has an activity of targeting DNA at a physiological temperature.
- the Argonaute protein is of prokaryotic origin.
- the Argonaute protein-guide RNA complex disclosed in the present disclosure can specifically regulate gene expression in a target-specific manner, and can also localize effectors that act on DNA, such as via an aptamer added to the guide RNA. Therefore, it can be expected to be applied to various genome editing.
- FIG. 1 is a schematic diagram showing the fusion of an aptamer to the Argonaute protein-guide RNA complex of the present disclosure.
- FIG. 2 is a schematic diagram showing purification of recombinant RsAgo protein.
- FIG. 3 is a schematic diagram showing a confirmation test of nucleic acid binding ability.
- FIG. 4 shows the test results of the nucleic acid binding ability of the RsAgo protein.
- FIG. 5 shows the test results of the binding affinity of the RsAgo protein to the target sequence.
- FIG. 6 shows the sequence-dependent test results of binding of the RsAgo protein to the target sequence.
- FIG. 7 is a schematic diagram showing guide RNA-aptamer synthesis by In vitro translation.
- FIG. 8 is a diagram showing the results of synthesis of guide RNA to which an aptamer is added.
- FIG. 9 is a diagram showing the binding result of the guide RNA-aptamer to the target sequence.
- FIG. 10 shows the results showing sequence-specific DNA binding by RNA with RsAgo and aptamer added.
- FIG. 11 is a diagram showing the result of binding of the RsAgo protein to the partial single-stranded region.
- FIG. 12 is a result showing specific binding to a single-stranded DNA containing a target sequence of RsAgo protein.
- FIG. 13 is a diagram showing the results of action of the RsAgo protein on the gene expression region.
- the "Argonaute protein” is a constituent protein of RISC (RNA-induced silencing complex), which is a central structure in RNA silencing via small RNA. It binds to a single-stranded RNA that acts as a guide to form RISC, and this complex catalyzes the cleavage of mRNA with a sequence complementary to the single-stranded RNA bound to Argonaute. It is an essential regulator of gene expression in plants and animals.
- Ago is composed of four domains (N domain, PAZ domain, MID domain, PIWI domain) and two linkers (L1 linker and L2 linker), and has a molecular weight of about 100 kDa.
- RNAs such as siRNA and miRNA are usually biosynthesized as double-stranded RNA and bind to Ago as double-stranded RNA.
- one strand (passenger strand) of the double-stranded RNA strand is torn off in Ago, mature RISC in which only the other strand (guide strand) is incorporated into Ago is formed.
- the RISC thus formed uses the sequence complementarity of the guide strand to find a specific target mRNA, which causes destabilization by suppressing translation or shortening the poly A strand (miRNA pathway).
- RNAi pathway cleave target mRNA
- any Ago is included.
- UniProt's Entry PS50822 https://prosite.expasy.org/PS50822
- Rhodobacter sphereeroides ATCC 17025 GenBank: ABP72561.1, https://www.uniprot). .org / uniprot / Q9UKV8
- guide RNA refers to an RNA molecule containing a sequence complementary to a target and a motif sequence necessary for forming a complex with an effector protein or a structure therefor.
- the guide RNA is an RNA that induces the Argonaute protein to specifically target the DNA sequence, and has a function of binding to the Argonaute protein of the present disclosure and guiding the protein to the target DNA.
- the "target proximity motif sequence” refers to a sequence that is present in a target double-stranded polynucleotide and is recognizable by the Argonaute protein and / or the Argonaute protein-guide RNA complex.
- the length and base sequence of the target proximity motif sequence differ depending on the bacterial species from which the Argonaute protein is derived. For example, in the case of RsAgo derived from Rhodobacter sphaeroides, it is sufficient to have only T on the 5'side as the target proximity motif sequence.
- the term "endonuclease” means an enzyme that cleaves the middle of a nucleotide chain.
- the Argonaute protein of the present disclosure has endonuclease activity, it has an enzymatic activity that is induced by a guide RNA and cleaves a DNA strand.
- “manipulation of gene function” includes cleavage, modification, and / or modification of a DNA sequence and suppression, control, and / or regulation of expression of a gene consisting of the DNA sequence. ..
- protein means a polymer of amino acid residues, and is used interchangeably with “polypeptide” and “peptide”.
- one or more amino acids means an amino acid polymer, which is a chemically analog or modified derivative of a naturally occurring corresponding amino acid.
- DNA sequence means a nucleotide sequence of any length, which may be a deoxyribonucleotide or a ribonucleotide, and may be linear, circular, or branched. It is a chain or a double chain.
- N means any one base selected from the group consisting of adenine, cytosine, thymine and guanine
- A means adenine
- G means guanine
- C means guanine.
- Cytosine, "T” means thymine
- R means a base having a purine skeleton (adenine or guanine)
- Y means a base having a pyrimidine skeleton (cytosine or thymine).
- polynucleotide means a deoxyribonucleotide or ribonucleotide polymer that is linear or cyclic and is in either single-stranded or double-stranded form, with respect to the length of the polymer. It is not interpreted as a limitation. It also includes known analogs of natural nucleotides as well as nucleotides (eg, phosphorothioate skeletons) that are modified in at least one of the base, sugar and phosphate moieties. In general, analogs of a particular nucleotide have the same base pairing specificity, for example, analogs of A base pair with T.
- an "additional sequence” is any sequence that can be added to a guide RNA, allowing the guide RNA to specifically bind to a particular molecule and / or a catalyst. It is meant to have activity.
- the additional sequence includes any nucleic acid aptamer.
- a method for manipulating gene function by acting site-specifically on a target DNA molecule the step of providing a complex containing an Argonaut protein, a guide RNA, and an additional sequence, and a target.
- a method comprising contacting a DNA molecule with the complex, wherein the guide RNA is designed to direct the complex to a region of the target DNA molecule containing a site of interest.
- the method of the present disclosure is useful as a genome editing technique.
- the CRISPR system is mainly used, but in the CRISPR system, about 20 RNA molecules following the PAM sequence of about 2 to 5 bases that define the target specificity are targeted. Due to the limitation of being used for, there will be gene loci for which target design is impossible. In addition, if there is a similar sequence near the target cleavage sequence, the similar sequence may be truncated. Furthermore, in the genome editing technology using the CRISPR system, those that have been put into practical use have a relatively large molecular weight, and there are still problems in intracellular delivery and immunogenicity.
- Some bacterial Argonaute proteins can recognize DNA sequences using guide RNA.
- this bacterium-derived Argonaute protein can be utilized as a novel genome editing mechanism.
- the Argonaute protein (Ago) used in the present disclosure may be derived from any organism as long as it has RNA-induced DNA targeting activity, and is derived from a prokaryote. May be. It is preferable that the Argonaute protein is derived from a bacterium.
- Argonaute protein MpAgo derived from Marinitoga piezophila, TpAgo derived from Thermotoga profunda, RsAgo derived from Rhodobacter sphaeroides, and the like can be used.
- Argonaute MpAgo derived from Marinitoga piezophila, TpAgo derived from Thermotoga profunda, RsAgo derived from Rhodobacter sphaeroides, and the like.
- Argonaute MpAgo derived from Marinitoga piezophila
- RsAgo derived from Rhodobacter sphaeroides and the like.
- ⁇ Argonaute Mesorhizobium sp ⁇ Bradyrhizobium centrolobii ⁇ Calothrix desertica PCC 7102 ⁇ Planctomycetes bacterium Mal33 ⁇ Elusimicrobia bacterium RBG_16_66_12 ⁇ Dehalococco
- the Argonaute protein has a molecular weight of about 100 kDa, and can be significantly smaller than the 160 kDa of CRISPR-Cas9 of Streptococcus pyogenes widely used in conventional genome editing technology.
- the guide RNA that binds to the Argonaute protein also becomes smaller because it does not have a Scaffold structural sequence or the like.
- the sequence that can be the target of the Argonaut protein-guide RNA complex of the present disclosure need only have T on the 5'side as the target proximity motif sequence, and is required for target recognition in the standard Streptococcus pyogenes CRISPR-Cas9. The constraint is smaller than that of GG, which is a simple PAM sequence.
- a complex of the Argonaute protein and the guide RNA can be formed extracellularly or in vitro.
- the target DNA molecule is present in vivo and the Argonaute protein-guide RNA complex formed extracellularly or in vitro binds in vivo.
- an additional sequence can be further bound to the guide RNA to form an effector such as an enzyme site that acts on the target DNA.
- the additional sequence may be any sequence as long as it can specifically bind to a specific molecule, and examples thereof include sequences and structures recognized by aptamers, ribozymes, and RNA-binding proteins. Can be done.
- as the aptamer MS2 aptamer, PP7, TAR and the like can be used.
- the complex of Argonaute protein and aptamer fusion guide RNA can specifically bind to the target DNA sequence.
- the Argonaute protein can have DNA-targeting activity, preferably DNA-targeting activity at physiological temperatures.
- the complex of the Argonaute protein of the present disclosure and a guide RNA can regulate the expression of the gene by inducing and targeting the gene expression in a closed double-stranded DNA. ..
- the expression of the gene of interest can be improved or activated.
- the Argonaute-guide RNA complex of the present disclosure can specifically bind to the double-stranded DNA that has induced gene expression and suppress the gene expression.
- the guide RNA so that it binds to the strand opposite the transcription template of the target gene, the expression of the target gene can be suppressed.
- the guide RNA may be any RNA that directs the Argonaute protein to specifically target the DNA sequence, preferably the Argonaute-guide RNA complex at the site of interest in the target DNA molecule. Designed to guide to areas containing. The guide RNA recognizes the target DNA having only T on the 5'side as the target proximity motif sequence and binds to its complementary sequence. In one embodiment, the guide RNA has a sequence complementary to the target DNA at its 5'end and binds to the target DNA via the complementary sequence to make the Argonaute protein of the present disclosure into the target DNA. Guide.
- the DNA when the Argonaute protein functions as a DNA endonuclease, the DNA can be cleaved at the site where the target DNA is present, for example, the function of the target DNA can be specifically lost.
- Guide RNA is designed and prepared based on the sequence information of the target DNA to be cleaved or modified. Specific examples thereof include sequences as used in the examples.
- the Argonaute protein-guide RNA complex of the present disclosure can be provided as a complex containing an Argonaute protein, a guide RNA, and an additional sequence.
- Any sequence such as an aptamer can be prepared to form a complex extracellularly or intracellularly.
- the step of contacting the Argonaute protein-guide RNA complex with the target DNA molecule is such that the Argonaute protein-guide RNA complex of the present disclosure is expressed on the DNA containing the target sequence, for example, gene expression.
- the Argonaute protein-guide RNA complex of the present disclosure can thus control its gene expression by binding to the DNA containing the target sequence during gene expression.
- a method for regulating the expression of a target DNA molecule the step of providing a complex comprising an Argonaute protein, a guide RNA and an additional sequence, and a double-stranded DNA in the target DNA molecule.
- the guide RNA comprises a step of dissociating at least a part of the sequence and a step of contacting the complex with a double-stranded DNA sequence at least partially dissociated, wherein the guide RNA dissociates at least a part of the complex.
- a method is provided that is designed to direct to a region containing the double-stranded DNA sequence.
- the step of dissociating at least a part of a double-stranded DNA sequence in a target DNA molecule includes, for example, partially dissociating the double-stranded DNA by gene expression or the like.
- the step of contacting an Argonaute protein-guide RNA complex with a double-stranded DNA sequence that is at least partially dissociated dissociates at least a partially dissociated Argonaute protein-guide RNA complex.
- This includes binding the double-stranded DNA sequence to a partially dissociated state due to, for example, gene expression.
- the Argonaute protein-guide RNA complex of the present disclosure can thus control its gene expression by binding to the DNA containing the target sequence during gene expression.
- the complex with the Argonaute protein and the guide RNA of the present disclosure can be obtained by various methods, but preferably can be obtained by the method described in this example. In other embodiments, the complex with the Argonaute protein or guide RNA of the present disclosure can be obtained by any method as long as it exerts the actions and effects shown herein.
- the Argonaute protein-guide RNA complex of the present disclosure targets a site in which the double-stranded structure is dissociated by gene expression or DNA replication in a target cell, and the gene containing the target site is targeted. By suppressing the expression of, the cell function can be changed and the gene function analysis can be performed.
- the Argonaute protein-guide RNA complex of the present disclosure targets a sequence possessed only by a specific cell group in a heterogeneous cell population in order to target only a specific cell group. Gene function can be controlled.
- the Argonaute protein-guide RNA complex of the present disclosure can also cause an increase in target site-specific gene expression by binding to a transcription factor via an aptamer or the like.
- the DNA of the target sequence and its surroundings is modified by binding the Argonaute protein-guide RNA complex of the present disclosure to a nuclease, recombinase, deaminase, glycosyllase, etc. via an aptamer or the like. Can be done.
- a chromatin modifying factor such as a methylating enzyme, a demethylase, or a histone acetylase, the chromatin modification state in and around the target sequence can be changed.
- the present disclosure provides a method of modifying the target site of double-stranded DNA (eg, chromosomal DNA, mitochondrial DNA, chloroplast DNA; hereinafter collectively referred to as "genomic DNA”). do.
- the method comprises contacting the Argonaute protein with the guide RNA complex with the double-stranded DNA.
- modification of double-stranded DNA means that one nucleotide (eg, dA, dC, dG or dT) or nucleotide sequence on the DNA strand is replaced with another nucleotide or nucleotide sequence, or It means that another nucleotide or nucleotide sequence is inserted between one nucleotide on the DNA strand.
- the double-stranded DNA to be modified is not particularly limited, but is preferably genomic DNA.
- the term "donor DNA” means a DNA containing a foreign insertion sequence, and the donor DNA usually has two regions upstream and downstream of the target site, which are adjacent to the target site (hereinafter, “adjacent”). It contains two types of sequences (hereinafter also referred to as “homology arms”) that are homologous to the sequences of "regions"). When distinguishing each homology arm, it may be distinguished by "5'homology arm” and “3'homology arm”. Further, the "target site” of the double-stranded DNA means a region to be replaced by an insertion sequence contained in the donor DNA, or an interval between nucleotides into which the insertion sequence is to be inserted, and the target site. Does not include the adjacent sequence.
- sequence homologous to the adjacent region of the target site is not only a sequence that is completely identical, but is preferably 80% or more (eg, 85) with respect to the sequence that is completely identical as long as homologous recombination can occur in the cell. % Or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more) may be a sequence having the same identity.
- the donor DNA may be linear (eg, synthetic double-stranded DNA), circular (eg, plasmid DNA), or single-stranded DNA (eg, single-stranded oligodeoxynucleotide). (SsODN)) or double-stranded DNA.
- the donor DNA can be appropriately designed depending on the base length of the insertion sequence, the homologous recombination activity of the host cell, and the like. For example, if the insertion sequence has a length of 100 bases or less, ssODN or synthetic double-stranded DNA is usually used, and if it is longer than that, synthetic double-stranded DNA or plasmid DNA is usually used.
- the length of the donor DNA is also not particularly limited, and can be appropriately designed depending on the length of the insertion sequence and the like.
- the length of the inserted sequence is not particularly limited, and is usually in the range of 1 base length to tens of thousands of bases (for example, in the case of ssODN, 100 bases or less (eg, 70 bases or less, 50 bases or less)). It can be appropriately designed according to the purpose.
- the length of each homology arm is also not particularly limited, and when the donor DNA is ssODN, one having a length of 10 to 150 bases is usually used, and when the donor DNA is a synthetic double-stranded DNA, it is usually 10 to.
- the donor DNA is a plasmid DNA
- a DNA having a length of 5,000 bases is usually used, and a DNA having a length of 100 to 5,000 bases, preferably 500 bases to 1,000 bases is preferably used.
- donor DNAs refer to publicly known documents (eg, Ochiai H, Int J Mol Sci, 16: 21128-21137 (2015), Hockemeyer D et al., Nat Biotefchnol, 27: 851-857 (2009)). Can be designed.
- the "nucleic acid sequence recognition module” means a molecule or molecular complex having the ability to specifically recognize and bind to a specific nucleotide sequence (that is, a target nucleotide sequence) on a DNA strand.
- a specific nucleotide sequence that is, a target nucleotide sequence
- the Argonaute protein linked to the module is transferred to the site targeted by the double-stranded DNA Argonaute protein or the like (that is, the target nucleotide sequence and the nucleotides in the vicinity thereof). Allows for specific action.
- the target site can be modified by introducing a complex of Argonaute protein and a nucleic acid sequence recognition module and donor DNA into cells.
- nucleobase modifying enzyme complex is a nucleobase conversion reaction or nucleobase debasement to which a specific nucleotide sequence recognition ability is imparted, which comprises a complex in which the above nucleic acid sequence recognition module and an Argonaute protein are linked. It means a molecular complex having a catalytic function of a reaction.
- the “complex” includes not only those composed of a plurality of molecules but also those having a nucleic acid sequence recognition module and an Argonaute protein in a single molecule, such as a fusion protein.
- the origin of the Argonaute protein is not particularly limited, and for example, MpAgo derived from Marinitoga pizophila, TpAgo derived from Thermotoga profunda, RsAgo derived from Rhodobacter sphaeroides, and the like can be used.
- Argonaute protein used in the present disclosure Argonaute protein derived from Mesorhizobium sp, Bradyrhizobium centrolobii, Calothrix desertica PCC 7102, Planctomycetes bacterium Mal33, Elusimicrobia bacterium RBG_16_66_12, Dehalococcoides cart, etc. can be used.
- families containing homologues of these Argonaute proteins can also be used.
- an oligo DNA primer is synthesized based on the cDNA sequence information of the enzyme to be used, and the enzyme is used. It can be cloned by using the total RNA or mRNA fraction prepared from the producing cells as a template and amplifying it by the RT-PCR method.
- the DNA encoding the Argonaute protein is based on the cDNA sequence registered in the NCBI database (Rhodobacter sphaeroides ATCC 17025, https://www.ncbi.nlm.nih.gov/protein/ABP72561.1).
- Appropriate primers can be designed for upstream and downstream of CDS and cloned from mRNA by the RT-PCR method.
- the donor DNA can also be cloned in the same manner as described above based on the sequence information of the target site and the like.
- Expression vectors include E. coli-derived viruses (eg, pBR322, pBR325, pUC12, pUC13); Bacteriophage-derived plasmids (eg, pUB110, pTP5, pC194); Yeast-derived plasmids (eg, pSH19, pSH15); Insect cell expression.
- Plasmids eg pFast-Bac
- animal cell expression plasmids eg pA1-11, pXT1, pRc / CMV, pRc / RSV, pcDNAI / Neo
- bacteriophage such as ⁇ phage
- insect virus vectors such as baculovirus (eg) Examples: BmNPV, AcNPV); animal virus vectors such as retrovirus, vaccinia virus, adenovirus and the like are used.
- the promoter may be any promoter as long as it is suitable for the host used for gene expression. Since the conventional method involving DSB may significantly reduce the viability of the host cell due to toxicity, it is desirable to increase the number of cells by the start of induction using an inducible promoter, but the nucleic acid modification of the present disclosure is made. Since sufficient cell proliferation can be obtained even if the enzyme complex is expressed, the constituent promoter can be used without limitation.
- SR ⁇ promoter when the host is an animal cell, SR ⁇ promoter, SV40 promoter, LTR promoter, CMV (cytomegalovirus) promoter, RSV (Rous sarcoma virus) promoter, MoMuLV (Morony mouse leukemia virus) LTR, HSV-TK (herpes simplex virus). Virus thymidin kinase) promoter and the like are used.
- CMV cytomegalovirus
- RSV Raster sarcoma virus
- MoMuLV MoMorony mouse leukemia virus
- HSV-TK herpes simplex virus
- Virus thymidin kinase thymidin kinase
- a trp promoter When the host is Escherichia coli, a trp promoter, a lac promoter, a recA promoter, a ⁇ PL promoter, a lpp promoter, a T7 promoter and the like are preferable.
- the SPO1 promoter, SPO2 promoter, penP promoter and the like are preferable.
- Gal1 / 10 promoter When the host is yeast, Gal1 / 10 promoter, PHO5 promoter, PGK promoter, GAP promoter, ADH promoter and the like are preferable.
- a polyhedrin promoter When the host is an insect cell, a polyhedrin promoter, a P10 promoter, or the like is preferable.
- the CaMV35S promoter When the host is a plant cell, the CaMV35S promoter, CaMV19S promoter, NOS promoter and the like are preferable.
- a vector containing an enhancer, a splicing signal, a terminator, a poly A addition signal, a drug resistance gene, a selection marker such as an auxotrophic complementary gene, an origin of replication, or the like is used, if desired. Can be done.
- RNA encoding the nucleic acid sequence recognition module and / or the Argonaute protein or the like can be obtained by using, for example, a vector encoding the DNA encoding the nucleic acid sequence recognition module and / or the Argonaute protein or the like described above as a template in an in vitro transcription system known per se. It can be prepared by transcribing to mRNA.
- an expression vector containing a nucleic acid sequence recognition module and / or a DNA encoding an Argonaute protein or the like into a host cell and culturing the host cell, a complex of the nucleic acid sequence recognition module and the Argonaute protein or the like can be obtained in the cell. Can be expressed.
- Escherichia spp. for example, Escherichia spp., Bacillus spp., Yeast, insect cells, insects, animal cells and the like are used.
- Escherichia spp. are Escherichia coli K12 / DH1 [Proc. Natl. Acad. Sci. USA, 60, 160 (1968)], Escherichia coli JM103 [Nucleic Acids Research, 9,309 ( 1981)], Escherichia coli JA221 [Journal of Molecular Biology, 120, 517 (1978)], Escherichia coli HB101 [Journal of Molecular Biology, 41, 459 (1969)], Escherichia coli C600 [Genetics, 39, 440] (1954)] etc. are used.
- Bacillus genus for example, Bacillus subtilis MI114 [Gene, 24, 255 (1983)], Bacillus subtilis 207-21 [Journal of Biochemistry, 95, 87 (1984)] and the like are used.
- yeast examples include Saccharomyces cerevisiae AH22, AH22R-, NA87-11A, DKD - 5D, 20B-12, Schizosaccharomyces pombe NCYC1913, NCYC2036, Pichia pastoris. KM71 etc. are used.
- insect cells for example, when the virus is AcNPV, Spodoptera frugiperda cells (Sf cells), MG1 cells derived from the middle intestine of Trichoplusia ni, and High Five TM cells derived from eggs of Trichoplusia ni. , Cells derived from Mamestra brassicae, cells derived from Estigmena acrea, etc. are used.
- Sf cells for example, Sf9 cells (ATCC CRL1711), Sf21 cells [above, In Vivo, 13, 213-217 (1977)] and the like are used.
- insects for example, silk moth larvae, Drosophila, crickets, etc. are used [Nature, 315, 592 (1985)].
- animal cells examples include monkey COS-7 cells, monkey Vero cells, Chinese hamster ovary (CHO) cells, dhfr gene-deficient CHO cells, mouse L cells, mouse AtT-20 cells, mouse myeloma cells, rat GH3 cells, and humans.
- Fetal kidney-derived cells eg, HEK293 cells
- human liver cancer-derived cells eg, HepG2
- cell lines such as human FL cells
- pluripotent stem cells such as human and other mammalian iPS cells and ES cells
- various Primary cultured cells prepared from tissue are used.
- zebrafish embryos, Xenopus oocytes and the like can also be used.
- the plant cells were prepared from various plants (for example, grains such as rice, wheat and corn, commercial crops such as tomato, cucumber and eggplant, garden plants such as carnation and Vietnamese ginkgo, experimental plants such as tobacco and white indigo plant). Suspended cultured cells, callus, protoplasts, leaf sections, root sections, etc. are used.
- the introduction of the expression vector depends on the type of host, known methods (for example, lysoteam method, competent method, PEG method, CaCl2 coprecipitation method, electroporation method, microinjection method, particle gun method, lipofection method, etc. It can be carried out according to the Agrobacterium method, etc.).
- Donor DNA can also be introduced into cells by a similar method. When the expression vector and the donor DNA are introduced as different molecules, the expression vector and the donor DNA may be introduced at the same time or at different timings.
- Escherichia coli can be transformed according to the method described in, for example, Proc. Natl. Acad. Sci. USA, 69, 2110 (1972) or Gene, 17, 107 (1982).
- the Bacillus genus can be vector-introduced according to the method described in, for example, Molecular & General Genetics, 168, 111 (1979).
- the vector can be introduced according to the method described in Methods in Enzymology, 194, 182-187 (1991), Proc. Natl. Acad. Sci. USA, 75, 1929 (1978).
- Insect cells and insects can be vector-introduced according to the method described in, for example, Bio / Technology, 6, 47-55 (1988).
- Animal cells can be vector-introduced according to the method described in, for example, Cell Engineering Supplement 8 New Cell Engineering Experiment Protocol, 263-267 (1995) (published by Shujunsha), Virology, 52, 456 (1973).
- Culturing of cells into which the vector and donor DNA have been introduced can be carried out according to a known method according to the type of host.
- a liquid medium is preferable as the medium used for culturing.
- the medium preferably contains a carbon source, a nitrogen source, an inorganic substance and the like necessary for the growth of the transformant.
- the carbon source for example, glucose, dextrin, soluble starch, sucrose, etc .
- the nitrogen source for example, ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean meal, etc.
- Inorganic or organic substances such as potato extracts; examples of the inorganic substances include calcium chloride, sodium dihydrogen phosphate, magnesium chloride and the like, respectively.
- yeast extract, vitamins, growth promoting factors and the like may be added to the medium.
- the pH of the medium is preferably about 5 to about 8.
- E. coli As a medium for culturing E. coli, for example, an M9 medium containing glucose and casamino acid [Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York 1972] is preferable. If necessary, a drug such as 3 ⁇ -indrill acrylic acid may be added to the medium to allow the promoter to work efficiently. Culturing of E. coli is usually carried out at about 15 to about 43 ° C. If necessary, ventilation or stirring may be performed.
- Culture of Bacillus spp. Is usually carried out at about 30 to about 40 ° C. If necessary, ventilation or stirring may be performed.
- a medium for culturing yeast for example, Burkholder's minimum medium [Proc. Natl. Acad. Sci. USA, 77, 4505 (1980)] or SD medium containing 0.5% casamino acid [ Proc. Natl. Acad. Sci. USA, 81, 5330 (1984)] and the like.
- the pH of the medium is preferably about 5 to about 8.
- Culturing is usually carried out at about 20 ° C to about 35 ° C. If necessary, aeration or stirring may be performed.
- a medium for culturing insect cells or insects for example, Grace's Insect Medium [Nature, 195, 788 (1962)] to which an additive such as deactivated 10% bovine serum is appropriately added is used.
- the pH of the medium is preferably from about 6.2 to about 6.4.
- Culturing is usually carried out at about 27 ° C. Ventilation and agitation may be performed as needed.
- the minimum essential medium (MEM) (Science, 122, 501 (1952)] containing about 5 to about 20% fetal bovine serum, Dulbecco's modified Eagle's medium (DMEM) [ Virology, 8,396 (1959)], RPMI 1640 medium [The Journal of the American Medical Association, 199, 519 (1967)], 199 medium [Proceeding of the Society for the Biological Medicine, 73, 1 (1950)], etc.
- the pH of the medium is preferably about 6 to about 8.
- Culturing is usually carried out at about 30 ° C to about 40 ° C. Ventilation and agitation may be performed as needed.
- MS medium As the medium for culturing plant cells, MS medium, LS medium, B5 medium and the like are used.
- the pH of the medium is preferably about 5 to about 8.
- Culturing is usually carried out at about 20 ° C to about 30 ° C. Ventilation and agitation may be performed as needed.
- a complex of a nucleic acid sequence recognition module and an Argonaute protein or the like, that is, a nucleic acid modifying enzyme complex can be expressed intracellularly.
- RNA encoding a nucleic acid sequence recognition module and / or Argonaute protein or the like into a host cell can be performed by a microinjection method, a lipofection method, or the like. RNA introduction can be repeated once or multiple times (eg, 2-5 times) at appropriate intervals.
- the nucleic acid sequence recognition module of the present disclosure using an Argonaute protein is provided as a complex of an Argonaute protein, a gRNA-ap, and a BP-Effector.
- the BP effector protein used in the present disclosure is not particularly limited as long as it can form a complex with a guide RNA and change the expression and function of the target gene, but is preferably nuclease, recombinase, deaminase, glycosyllase, and methylation. Enzymes, demethylases, histone acetylases, etc.
- the DNA encoding the BP effector protein (including the mutant, the same applies hereinafter) can be cloned from the cell producing the enzyme by the same method as described above. It can be obtained by introducing a mutation to convert one amino acid with another.
- the DNA encoding the BP effector protein is used in combination with the chemical synthesis, the PCR method, or the Gibson Assembly method by the same method as described above for the DNA encoding the nucleic acid sequence recognition module and the DNA encoding the Argonaute protein. It can also be constructed as DNA with codon usage suitable for expression in host cells.
- the obtained BP effector protein and / or nucleic acid modifying enzyme can be inserted downstream of the promoter of the same expression vector as described above, depending on the target cell.
- the length of the targeting sequence is not particularly limited as long as it can specifically bind to the target nucleotide sequence, but is, for example, 15 to 30 nucleotides, preferably 18 to 25 nucleotides.
- the DNA encoding the guide RNA can also be inserted into the same expression vector as above, but as a promoter, the transcription initiation site is T (U as RNA), or the 5'end is U by processing. Is preferable.
- the DNA encoding the guide RNA is a sequence complementary to the target strand of the target nucleotide sequence, and the oligo RNA sequence is designed so that the 5'end is phosphorylated U, and a DNA / RNA synthesizer is used. Can be used to chemically synthesize.
- the DNA or RNA encoding the Argonaute protein or the like, the guide RNA or the DNA encoding the guide RNA or the DNA encoding the guide RNA can be introduced into the host cell by the same method as described above, depending on the host.
- a common Argonaute protein or the like can be used.
- an expression vector containing a DNA encoding the nucleic acid-modifying enzyme complex is introduced into the host cell as described above, but mutations are efficiently introduced. In order to do so, it is desirable that the expression of the nucleic acid modifying enzyme complex is maintained at a certain level or higher for a certain period of time or longer. From this point of view, although it is certain that the expression vector is integrated into the host genome, sustained expression of the nucleic acid modifying enzyme complex increases the risk of off-target cleavage, so that modification of the target site is successfully achieved. After that, it is preferable to remove it promptly. Examples of means for removing the DNA integrated into the host genome include a method using a Cre-loxP system, a FLP-FRT system, a method using a transposon, and the like.
- off-targeting is performed by transiently expressing the nucleic acid modifying enzyme complex of the present disclosure in the host cell for a period required for the nucleic acid reaction to occur at a desired time and the modification of the target site to be fixed. Editing of the host genome can be efficiently realized while avoiding the risk of cleavage.
- Those skilled in the art can appropriately determine a suitable expression induction period based on the culture conditions and the like used.
- the expression induction period of the nucleic acid encoding the nucleic acid modifying enzyme complex of the present disclosure is extended beyond the above-mentioned "period required for the modification of the target site to be fixed" as long as it does not cause side effects in the host cell. May be good.
- a construct containing a nucleic acid encoding the nucleic acid-modifying enzyme complex in a form in which the expression period can be controlled examples thereof include a method of preparing (expression vector) and introducing it into a host.
- Specific examples of the "form in which the expression period can be controlled” include those in which the nucleic acid encoding the nucleic acid modifying enzyme complex of the present disclosure is placed under the control of an inducible regulatory region.
- the "inducible regulatory region” is not particularly limited, and examples thereof include an operon between a temperature-sensitive (ts) mutant repressor and an operator controlled by the repressor.
- ts mutant repressor examples include, but are not limited to, ts variants of the cI repressor derived from ⁇ phage.
- ⁇ phage cI repressor ts
- it binds to the operator at 30 ° C or lower (eg, 28 ° C) and suppresses downstream gene expression, but at a high temperature of 37 ° C or higher (eg, 42 ° C), the operator. Gene expression is induced to dissociate from. Therefore, host cells into which a nucleic acid encoding a nucleic acid-modifying enzyme complex has been introduced are usually cultured at 30 ° C. or lower, and at an appropriate time, the temperature is raised to 37 ° C.
- the temperature is quickly returned to 30 ° C or lower to minimize the period during which the expression of the target gene is suppressed, and when targeting an essential gene for the host cell.
- it can be edited efficiently while suppressing side effects.
- the nucleic acid-modifying enzyme is loaded by mounting the temperature-sensitive variant of the protein required for autonomous replication of the vector into a vector containing DNA encoding the nucleic acid-modifying enzyme complex of the present disclosure. After the expression of the complex, autonomous replication is not possible promptly, and the vector spontaneously sheds with cell division.
- a temperature-sensitive mutant protein include, but are not limited to, a temperature-sensitive mutant of Rep101 ori, which is necessary for replication of pSC101 ori.
- Rep101 ori acts on pSC101 ori at 30 ° C or lower (eg, 28 ° C) to enable autonomous replication of the plasmid, but loses its function at 37 ° C or higher (eg, 42 ° C), and the plasmid becomes Autonomous replication becomes impossible. Therefore, when used in combination with the cI repressor (ts) of the above ⁇ phage, transient expression of the nucleic acid modifying enzyme complex of the present disclosure and plasmid removal can be performed simultaneously.
- the DNA encoding the nucleic acid modifying enzyme complex of the present disclosure is controlled by an inducible promoter (eg, lac promoter (induced by IPTG), cspA promoter (induced by cold shock), araBAD promoter (induced by arabinose), etc.).
- an inducible promoter eg, lac promoter (induced by IPTG), cspA promoter (induced by cold shock), araBAD promoter (induced by arabinose), etc.
- the nucleic acid-modifying enzyme complex is introduced into the host cell, and the inducer is added (or removed from the medium) to the medium at an appropriate time to induce the expression of the nucleic acid-modifying enzyme complex, and the nucleic acid-modifying enzyme complex is cultured for a certain period of time to carry out a nucleic acid-modifying reaction.
- Transient expression of the nucleic acid modifying enzyme complex can be achieved after the mutation is introduced into the target gene.
- the Argonaute-guide RNA complex comprises an Argonaute protein and a synthesized guide RNA polynucleotide, wherein the guide sequence is a target proximity motif sequence of the Argonaute-guide RNA complex.
- Argonaute-guided RNA complexes designed to direct a target DNA molecule having it are provided.
- the Argonaute-guide RNA complex for site-specific action of a target DNA molecule to manipulate gene function, comprising an Argonaute protein and a synthesized guide RNA polynucleotide, said.
- the guide sequence is designed so that the Argonaute-guide RNA complex points to a target DNA molecule having a target proximity motif sequence, and the complex binds to the target molecule to be site-specific to the target DNA molecule.
- Argonaute-guided RNA complexes are provided that act on and manipulate gene function.
- an Argonaute-guide RNA complex for regulating the expression of a target DNA molecule, comprising an Argonaute protein and a synthesized guide RNA polynucleotide, wherein the guide sequence is an Argonaute-guide RNA.
- Argonaute-guide RNA complex in which the complex is designed to direct a target DNA molecule having a target proximity motif sequence, and the expression of the target DNA molecule is regulated by the complex binding to the target molecule. The body is provided.
- the Argonaute-guide RNA complex of the present disclosure may be provided with the complex formed in vitro, or a gene sequence such that the vector DNA expresses each element of the complex. Can also be provided operably arranged to form a complex in vivo from the vector DNA.
- a system or kit for site-specific action of a target DNA molecule to manipulate gene function comprising an Argonaute protein, a guide RNA and an additional sequence, or two or more of them.
- the guide RNA comprises two or more complexes and means or reagents for contacting the target DNA molecule with the complex so that the guide RNA directs the complex to a region of the target DNA molecule containing the site of interest.
- a system or kit designed for is provided.
- a system or kit for regulating the expression of a target DNA molecule comprising two or more complexes comprising an Argonaute protein, a guide RNA and an additional sequence, or two or more of these, and the target DNA.
- the guide RNA comprises a means or reagent for dissociating at least a portion of a double-stranded DNA sequence in a molecule and a means or reagent for contacting the complex with a double-stranded DNA sequence at least partially dissociated.
- Systems or kits are provided that are designed to direct the complex to a region containing the double-stranded DNA sequence that is at least partially dissociated.
- the kit of the present disclosure is usually divided into two or more compartments and each element to be provided (eg, a vector, a nucleic acid construct, a cell into which the nucleic acid of interest has been transgenic, a reagent, etc. Signs, instructions, etc.) can be provided.
- the kit of the present disclosure may be provided with each element as a separate kit, in which case the complex of the present disclosure is derived from vector DNA or the like designed to be appropriately expressed in cells. It can be formed in vivo or in vitro.
- the system of the present disclosure forms the complex of the present disclosure in vivo or in vitro to regulate the expression of the target DNA molecule and / or site-specifically target the target DNA molecule. It is not particularly limited as long as it is provided with the means or reagents necessary for acting and manipulating the gene function.
- gene synthesis and fragment synthesis services such as GeneArt, GenScript, Integrated DNA Technologies (IDT) can also be used, and other, for example, Gait. , M. J. (1985). Organicleotide Synthesis: A Practical Approach, IRL Press; Gait, M. Gait. J. (1990). Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein, F.I. (1991). Oligonucleotides and Analogues: A Practical Approach, IRL Press; Adams, R.M. L. Et al. (1992). The Biochemistry of the Nucleic Acids, Chapman &Hall; Shabarova, Z. Et al. (1994).
- IDT Integrated DNA Technologies
- Example 1 Preparation of recombinant RsAgo protein
- the recombinant RsAgo protein was designed as shown in FIG. 2 and purified by the following procedure. Plasmid: pT7SU_RsAgo (SEQ ID NO: 1) Strine: Rosetta2 (DE3) pLysS
- Rosetta2 (DE3) pLysS was transformed with pT7SU_RsAgo by a heat shock method, then seeded on Kan50 + Cm34 plates and incubated overnight at 37 ° C.
- Protein purification was performed using the AKTA purifier. The conditions were as follows. HiTrap TALON_crude 1ml Column binding buffer: 50 mM Na-phos, pH 8.0; 500 mM NaCl; 5% glycerol Elution buffer: 50 mM Na-phos, pH 8.0; 500 mM NaCl; 5% glycerol, 500 mM Imidazole Elution: 2-100% B Granant 30ml Fractions were recovered based on the UV280 nm signal and purified proteins were confirmed by SDS-PAGE.
- Example 2 Confirmation of EMSA nucleic acid binding ability
- the nucleic acid binding ability of the RsAgo protein obtained in Example 1 was confirmed by the following procedure (FIG. 3).
- nucleic acid (oligo) The following nucleic acids were used to be bound. 3'-FAM-labeled synthetic RNA (18nt) 5'-UUACAACCUACUACCUCG- [FAM] (SEQ ID NO: 2) 5'-FAM-labeled synthetic DNA (18nt) 5'-[FAM]-CGAGGTAGTAGGTTGTAA (SEQ ID NO: 3)
- Reaction buffer 20 mM HEPES-KOH, pH7.5; 200 mM NaCl; 5 mM MgCl2 was used as the reaction buffer.
- RNA phosphorylation 3'-FAM-labeled synthetic RNA was phosphorylated by the following procedure. Takara T4 Polynucleotide kinase and ATP were mixed and reacted at 37 ° C. for 1 hour for phosphorylation. This was purified using the QIAGEN Nucleotide removal kit.
- Example 3 Confirmation of EMSA nucleic acid binding ability
- Example 3 Confirmation of EMSA nucleic acid binding ability
- Synthetic oligo DNA The following nucleic acids were used to be bound (SEQ ID NOS: 5 to 8 in order from the top). • Those with complementary sequences (20, 30, and 40 nt) -Non-complementary sequence (42nt)
- Example 4 Synthesis of gRNA-aptamer by In vitro translation
- the aptamer was fused to the guide RNA by In vitro translation as shown in FIG. 7 (for sequences, SEQ ID NOs: 9 to 12 in order from the top of FIG. 7).
- (1) Template plasmid A pHMk047_pT7_HH-hm014-MS2 template was used as the template plasmid (SEQ ID NO: 16). It was digested and linearized by SmaI, and linear DNA was introduced as a template according to the protocol of the Promega Ribomax Large scale RNA production system (T7) kit and reacted at 37 ° C. for 2 hours.
- T7 Promega Ribomax Large scale RNA production system
- the template DNA was digested with DNase I (at 37 ° C. for 15 minutes) and purified with the ZYMO research RNA clean and concentrator kit.
- (2) Hammerhead self-cleaving Purified RNA and 10xT4 ligase buffer (NEB) were mixed and incubated at room temperature (25 ° C.) for 30 minutes.
- (4) Results As shown in FIG. 8, it was confirmed that the guide RNA to which an aptamer was added could be generated (for sequences, SEQ ID NOs: 13 to 14 in order from the top of FIG. 8).
- Example 5 Binding to target sequence by gRNA-aptamer
- gRNA-aptamer obtained in Example 4 binding to the target sequence of RsAgo was confirmed (FIG. 9).
- sequence-specific DNA binding by RNA to which RsAgo and aptamer were added could be confirmed (for sequences, SEQ ID NOs: 5 to 8 in order from the top of FIG. 10).
- Target DNA The following DNA was used as the target DNA (SEQ ID NOS: 17 to 20 in order from the top). ⁇ Partially containing a single chain ⁇ Completely double-stranded
- EMSA Purified protein final 500 nM
- labeled guide RNA final 100 nM
- Target DNA was added to this (final 100 to 1000 nM). After adding sucrose to this mixture, tripartite complex formation was observed on a 6% TBE polyacrylamide gel.
- Example 7 Confirmation of EMSA nucleic acid binding ability
- a target DNA containing a partial single strand on the 5'side of the target sequence and a target DNA A target DNA containing a partial single strand was prepared on the 3'side of the target sequence, and the nucleic acid binding ability was confirmed.
- Purified protein Purified RsAgo protein was prepared and used.
- EMSA Purified protein final 500 nM
- labeled guide RNA final 100 nM
- Target DNA was added to this (final 100 to 1000 nM). After adding sucrose to this mixture, tripartite complex formation was observed on a 6% TBE polyacrylamide gel.
- reaction buffer 80 mM HEPES-KOH, pH7.5; 24 mM MgCl2; 2 mM spermidine; 40 mM DTT was used.
- EMSA Purified protein final 100 nM
- guide RNA final 4 ⁇ M
- a PCR product target DNA
- T7 RNA pol mix Promega # P1300
- rNTPs final 1 mM
- the method of this disclosure enables artificial manipulation of gene functions in all living organisms such as animals, plants, and microorganisms, it can be expected to have a wide range of applications such as medical applications, development of agricultural products, and modification of industrial microorganisms.
- SEQ ID NO: 1 Template plasmid used in Example 1
- SEQ ID NOs: 2-3 Synthetic RNA or synthetic DNA used in Example 1.
- SEQ ID NO: 4 Synthetic RNA used in Example 3
- SEQ ID NOs: 5-8 Synthetic oligo DNA used in Example 3
- SEQ ID NOs: 9-12 Synthetic DNA used in Example 7
- SEQ ID NOs: 13-14 Guide RNA aptamer used in Example 4
- SEQ ID NO: 15 Synthetic RNA used in Example 6.
- SEQ ID NO: 16 Template plasmid used in Example 4
- SEQ ID NOs: 21-24 Target DNA used in Example 7
- SEQ ID NOs: 25-26 Guide RNA aptamer used in Example 8
- SEQ ID NO: 27 Template plasmid used in Example 8
- SEQ ID NO: 28 PCR product of Example 8
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
(項目1)
標的DNA分子を部位特異的に作用して遺伝子機能を操作するための方法であって、
Argonauteタンパク質とガイドRNAと付加配列とを含む複合体を提供する工程と、
標的DNA分子に、該複合体を接触させる工程と
を含み、該ガイドRNAが、該複合体を標的DNA分子中の目的の部位を含む領域に誘導するように設計される、方法。
(項目2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目に記載の方法。
(項目3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の方法。
(項目4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の方法。
(項目5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の方法。
(項目6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の方法。
(項目7)
前記複合体は、生体外で形成される、上記項目のいずれか一項に記載の方法。
(項目8)
前記複合体は、生体外で形成され、前記標的DNA分子は生体内に存在する、上記項目のいずれか一項に記載の方法。
(項目9)
前記Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計される、上記項目のいずれか一項に記載の方法。
(項目10)
前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変および/またはその両方を含む、上記項目のいずれか一項に記載の方法。
(項目11)
前記遺伝子機能の操作は、遺伝子発現制御を含む、上記項目のいずれか一項に記載の方法。
(項目12)
前記遺伝子機能の操作は、遺伝子配列改変を含む、上記項目のいずれか一項に記載の方法。
(項目A1)
標的DNA分子の発現を調節するための方法であって、
Argonauteタンパク質とガイドRNAと付加配列とを含む複合体を提供する工程と、
標的DNA分子における二本鎖DNA配列の少なくとも一部を解離させる工程と、
少なくとも一部が解離した二本鎖DNA配列に、該複合体を接触させる工程と
を含み、該ガイドRNAが、該複合体を、少なくとも一部が解離した該二本鎖DNA配列を含む領域に誘導するように設計される、方法。
(項目A2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の方法。
(項目A3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の方法。
(項目A4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の方法。
(項目A5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の方法。
(項目A6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の方法。
(項目A7)
前記複合体は、生体外で形成される、上記項目のいずれか一項に記載の方法。
(項目A8)
前記複合体は、生体外で形成され、前記標的DNA分子は生体内に存在する、上記項目のいずれか一項に記載の方法。
(項目B1)
Argonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されている、Argonaute-ガイドRNA複合体。
(項目B2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目B3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目B4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の複合体。
(項目B5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の複合体。
(項目B6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の複合体。
(項目C1)
標的DNA分子を部位特異的に作用して遺伝子機能を操作するためのArgonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子に部位特異的に作用して遺伝子機能が操作される、Argonaute-ガイドRNA複合体。
(項目C2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目C3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目C4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の複合体。
(項目C5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の複合体。
(項目C6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の複合体。
(項目C7)
前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変、および/またはその両方を含む、上記項目のいずれか一項に記載の複合体。
(項目C8)
前記遺伝子機能の操作は、遺伝子発現制御を含む、上記項目のいずれか一項に記載の複合体。
(項目C9)
前記遺伝子機能の操作は、遺伝子配列改変を含む、上記項目のいずれか一項に記載の複合体。
(項目D1)
標的DNA分子の発現を調節するためのArgonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子の発現が調節される、Argonaute-ガイドRNA複合体。
(項目D2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目D3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の複合体。
(項目D4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の複合体。
(項目D5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の複合体。
(項目D6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の複合体。
(項目E1)
標的DNA分子を部位特異的に作用して遺伝子機能を操作するためのシステムまたはキットであって、
Argonauteタンパク質、ガイドRNAおよび付加配列、またはこれらのうち2以上を含む2以上の複合体と、
標的DNA分子に、該複合体を接触させる手段または試薬と
を含み、該ガイドRNAが、該複合体を標的DNA分子中の目的の部位を含む領域に誘導するように設計される、システムまたはキット。
(項目E2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E7)
前記複合体を、生体外で形成するための手段を含む、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E8)
前記複合体を、生体外で形成するための手段を含み、前記標的DNA分子は生体内に存在する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E9)
前記Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計される、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E10)
前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変および/またはその両方を含む、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E11)
前記遺伝子機能の操作は、遺伝子発現制御を含む、上記項目のいずれか一項に記載のシステムまたはキット。
(項目E12)
前記遺伝子機能の操作は、遺伝子配列改変を含む、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F1)
標的DNA分子の発現を調節するためのシステムまたはキットであって、
Argonauteタンパク質、ガイドRNAおよび付加配列、またはこれらのうち2以上を含む2以上の複合体と、
標的DNA分子における二本鎖DNA配列の少なくとも一部を解離させる手段または試薬と、
少なくとも一部が解離した二本鎖DNA配列に、該複合体を接触させる手段または試薬と
を含み、該ガイドRNAが、該複合体を、少なくとも一部が解離した該二本鎖DNA配列を含む領域に誘導するように設計される、システムまたはキット。
(項目F2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F7)
前記複合体を、生体外で形成する手段をさらに含む、上記項目のいずれか一項に記載のシステムまたはキット。
(項目F8)
前記複合体を、生体外で形成する手段をさらに含み、前記標的DNA分子は生体内に存在する、上記項目のいずれか一項に記載のシステムまたはキット。
(項目G1)
標的DNA分子を部位特異的に作用して遺伝子機能を操作するための、Argonaute-ガイドRNA複合体の使用であって、前記Argonaute-ガイドRNA複合体が、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子に部位特異的に作用して遺伝子機能が操作される、使用。
(項目G2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の使用。
(項目G3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の使用。
(項目G4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の使用。
(項目G5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の使用。
(項目G6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の使用。
(項目G7)
前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変、および/またはその両方を含む、上記項目のいずれか一項に記載の使用。
(項目G8)
前記遺伝子機能の操作は、遺伝子発現制御を含む、上記項目のいずれか一項に記載の複使用。
(項目G9)
前記遺伝子機能の操作は、遺伝子配列改変を含む、上記項目のいずれか一項に記載の使用。
(項目H1)
標的DNA分子の発現を調節するための、Argonaute-ガイドRNA複合体の使用であって、前記Argonaute-ガイドRNA複合体が、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子の発現が調節される、使用。
(項目H2)
前記Argonauteタンパク質がDNAを標的とする活性を有する、上記項目のいずれか一項に記載の使用。
(項目H3)
前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、上記項目のいずれか一項に記載の使用。
(項目H4)
前記Argonauteタンパク質が原核生物由来のものである、上記項目のいずれか一項に記載の使用。
(項目H5)
前記Argonauteタンパク質が細菌由来のものである、上記項目のいずれか一項に記載の使用。
(項目H6)
前記Argonauteタンパク質がRhodobactor由来のRsAgoである、上記項目のいずれか一項に記載の使用。
以下に本開示の好ましい実施形態を説明する。以下に提供される実施形態は、本開示のよりよい理解のために提供されるものであり、本開示の範囲は以下の記載に限定されるべきでない。したがって、当業者は、本明細書中の記載を参酌して、本開示の範囲内で適宜改変を行うことができることは明らかである。また、本開示の以下の実施形態は単独でも使用されあるいはそれらを組み合わせて使用することができる。
本明細書において用いられる分子生物学的手法、生化学的手法、微生物学的手法は、当該分野において周知であり慣用されるものであり、例えば、Sambrook J. et al.(1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harborおよびその3rd Ed.(2001); Ausubel, F.M.(1987).Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Ausubel, F.M.(1989). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, M.A.(1990).PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, F.M.(1992).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Ausubel, F.M. (1995).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Innis, M.A. et al.(1995).PCR Strategies, Academic Press; Ausubel, F.M.(1999).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, J.J. et al.(1999). PCR Applications: Protocols for Functional Genomics, Academic Press、別冊実験医学「遺伝子導入&発現解析実験法」羊土社、1997などに記載されており、これらは本明細書において関連する部分(全部であり得る)が参考として援用される。
本明細書において引用された、科学文献、特許、特許出願などの参考文献は、その全体が、各々具体的に記載されたのと同じ程度に本明細書において参考として援用される。
図1に示すようにgRNAにアプタマーを融合することでRsAgo複合体が標的配列を認識できるかどうか確認するため、図2のようにリコンビナントRsAgoタンパク質を設計し、以下の手順で精製した。
Plasmid: pT7SU_RsAgo(配列番号1)
Strain: Rosetta2(DE3) pLysS
まずRosetta2(DE3) pLysSをpT7SU_RsAgoでヒートショック法により形質転換後、Kan50+Cm34プレートに播種し、37℃で一晩インキュベートした。
得られた形質転換体をLB(Kan+Cm)+1%glucose(20ml)で30℃で一晩培養した。LB(Kan+Cm)+1%glucose 0.9Lにo/n培養液を10ml播種し、37℃でOD600 1.0まで培養した。これにIPTGを最終濃度0.5mMとなるように加え、25℃で一晩培養した(~21hr)。
遠心操作により菌体を回収した。その菌体を約40mlのLysis buffer(50mM Na-phos, pH8.0; 100mM NaCl; 10% glycerol; Complete protease inhibitor cocktail (Roche))で懸濁した。これにDNaseI(final 4units/ml), MgCl2(final 2mM)、およびlysozyme(final
2mg/ml)を添加し、懸濁液20mlを20mlのlysis bufferと混合して希釈した。液体窒素で凍結後、氷水で融解した。以上の操作を5回繰り返し、菌体を破砕した。
124k×gで4℃で1時間超遠心し、上清を回収した。その後、塩濃度を500mMに調整し、0.45μmフィルターで清澄化した。
AKTA purifierを用いてタンパク質精製を行った。条件は以下のとおりとした。
HiTrap TALON_crude 1ml カラム
結合バッファー: 50mM Na-phos, pH 8.0; 500 mM NaCl; 5% glycerol
溶出バッファー: 50mM Na-phos, pH 8.0; 500 mM NaCl; 5% glycerol, 500mM Imidazole
溶出:2-100% B グラジェント 30ml
UV280nmシグナルをもとにフラクションを回収し、SDS-PAGEで精製タンパク質を確認した。
回収したフラクションに精製したUlp1 proteaseを添加し、氷上で一晩インキュベートした。その後、SDS-PAGEによってタグの切断を確認した。
脱塩カラム(HiTrap Desalting 5ml)でimidazoleを除去した。その後、再度HiTrap TALON crudeカラムに通して、素通り画分を回収した。この画分を硫安沈殿により濃縮し、8/3x Storage buffer (54mM Tris-Cl, pH7.5; 1334mM NaCl; 14mM 2-mercaptoethanol) で懸濁した。
この懸濁物をAmicon 15(MWCO 10k)で濃縮し、1xStorage buffer (20mM Tris-Cl, pH7.5; 500mM NaCl; 5mM 2-mercaptoehanol; 50% glycerol)で透析してリコンビナントRsAgoタンパク質とした。
実施例1で得られたRsAgoタンパク質の核酸結合能を以下の手順で確認した(図3)。
(1)精製タンパク質
精製RsAgoタンパク質の希釈系列を作製して用いた。
結合させる核酸としては以下のものを用いた。
3’-FAM標識合成RNA(18nt) 5’-UUACAACCUACUACCUCG-[FAM](配列番号2)
5’-FAM標識合成DNA(18nt) 5’-[FAM]-CGAGGTAGTAGGTTGTAA(配列番号3)
反応バッファーとして、20mM HEPES-KOH, pH7.5; 200mM NaCl; 5mM MgCl2を用いた。
上記の反応バッファー存在化で精製タンパク質と合成オリゴヌクレオチドを混合し、25℃で20分間インキュベートした。この混合物にスクロースを添加した後、6%TBEポリアクリルアミドゲルにて複合体形成を観察した。Blue light LEDによって検出した。
3’-FAM標識合成RNAを以下の手順でリン酸化した。
Takara T4 Polynucleotide kinaseとATPを混合し、37℃で1時間反応させてリン酸化した。これをQIAGEN Nucleotide removal kitを用いて精製した。
図4に示すとおり、RsAgoはssRNA(18mer)とssDNA(18mer)に結合することがわかった。また図5の結果からは、RsAgoは5’-P ssRNAへの親和性が高いこともわかった。
さらに、実施例1で得られたRsAgoタンパク質の標的配列の配列依存性を確認するため、相補的配列と非相補的配列へのそれぞれの核酸結合能を確認した。
(1)精製タンパク質
精製RsAgoタンパク質の希釈系列を作製して用いた。
リン酸化核酸としては以下のものを用いた。
3’-FAM標識合成RNA(18nt) 5’-UUACAACCUACUACCUCG-[FAM](配列番号4)
反応バッファーとして、20 mM HEPES-KOH, pH 7.5; 200 mM NaCl; 5 mM MgCl2を用いた。
上記の反応バッファー存在化で精製タンパク質(final 200nM)と標識RNA(final 200nM)とを混合し、25℃で15分間インキュベートして複合体を形成させた。これに合成オリゴDNAを添加(final 1μMまたは10μM)した。この混合物にスクロースを添加した後、6%TBEポリアクリルアミドゲルにて三者複合体形成を観察した。Blue light LEDによって検出した。
泳動後のアクリルアミドゲルをCBB染色して、タンパク質を検出した。
図6に示すとおり、RsAgoはgRNA配列依存的にssDNAに結合することがわかった。
本実施例では、図7のようにして、In vitro transcriptionによってガイドRNAにアプタマーを融合させた(配列について、図7の上から順に配列番号9~12)。
(1)鋳型プラスミド
鋳型プラスミドとしてはpHMk047_pT7_HH-hm014-MS2 templateを用いた(配列番号16)。SmaIによって消化して直鎖化し、Promega Ribomax Large scale RNA production system(T7)kitのプロトコルに従い、直鎖DNAを鋳型として導入し、37℃で2時間反応させた。DNaseIで鋳型DNAを消化し(37℃で15分間)、ZYMO research RNA clean and concentrator kitで精製した。
(2)Hammerhead 自己切断
精製RNAと10xT4 ligase buffer (NEB)を混合し、室温(25℃)で30分間インキュベートした。
(3)リン酸化
T4 Polynucleotide kinase (NEB)を添加し、37℃で30分間、続いて65℃で20分間反応させてリン酸化した。これをQIAGEN Nucleotide removal kit を用いて精製した。
(4)結果
図8に示すとおり、アプタマーを付加したガイドRNAが生成できたことが確認できた(配列について、図8の上から順に配列番号13~14)。
実施例4で得られたgRNA-アプタマーを用いて、RsAgoの標的配列との結合を確認した(図9)。
図10に示すとおり、RsAgoとアプタマーを付加したRNAによる配列特異的なDNA結合を確認できた(配列について、図10の上から順に配列番号5~8)。
本実施例では、RsAgoが標的DNAと結合する場合に、二本鎖の標的DNAに結合できるかどうかを確認するため、部分的に一本鎖を含む標的DNAと完全な二本鎖の標的DNAを準備し、以下の手順で核酸結合能を確認した。
(1)精製タンパク質
精製RsAgoタンパク質を作製して用いた。
リン酸化ガイドRNAとしては、以下のものを用いた。
3’-FAM標識合成RNA(18nt) 5’-UUACAACCUACUACCUCG-[FAM](配列番号15)
反応バッファーとして、20mM HEPES-KOH, pH7.5; 200 mM NaCl; 5 mM MgCl2を用いた。
上記の反応バッファー存在化で精製タンパク質(final 500nM)と標識ガイドRNA(final 100nM)を混合し、25℃で15分間インキュベートして複合体を形成させた。これに標的DNAを添加(final 100~1000nM)した。この混合物にスクロースを添加した後、6%TBEポリアクリルアミドゲルにて三者複合体形成を観察した。
図11に示すとおり、RsAgoは二本鎖DNAに自力では結合できず、部分的一本鎖領域が結合に必要であることがわかった。
続いて、RsAgoが標的DNAに結合する場合に、どのような状態の一本鎖領域が必要となるのかを確認するため、標的配列の5’側に部分的一本鎖を含む標的DNAと、標的配列の3’側に部分的一本鎖を含む標的DNAとを準備し、核酸結合能を確認した。
(1)精製タンパク質
精製RsAgoタンパク質を作製して用いた。
リン酸化ガイドRNAとしては、以下のものを用いた。
3’-FAM標識 合成RNA(18nt) 5’-UUACAACCUACUACCUCG-[FAM](配列番号15)
(3)標的DNA
標的DNAとしては以下のものを用いた(上から順に配列番号21~24)。
・標的配列の5’側に部分的一本鎖を含むもの
・標的配列の3’側に部分的一本鎖を含むもの
反応バッファーとして、20mM HEPES-KOH,pH 7.5; 200mM NaCl; 5mM MgCl2を用いた。
上記の反応バッファー存在化で精製タンパク質(final 500nM)と標識ガイドRNA(final 100nM)を混合し、25℃で15分間インキュベートして複合体を形成させた。これに標的DNAを添加(final 100~1000nM)した。この混合物にスクロースを添加した後、6%TBEポリアクリルアミドゲルにて三者複合体形成を観察した。
図12に示したとおり、リコンビナントタンパク質として精製されたRsAgoと、5’末端がリン酸化されたUで始まる任意の標的配列に続いてMS2アプタマーが付加されたガイドRNAとを用いてIn vitroにおいて形成された複合体が、標的配列を含む一本鎖DNAないし部分的に一本鎖になった2本鎖DNAへの特異的な結合性が認められた。またRsAgoはゲノム上の二本鎖DNAの特にgRNAの5’-側に相補的な領域を開くことができれば標的DNAと結合できることがわかった。
RsAgoが標的DNAとの結合において、部分的に一本鎖領域が必要となることがわかったため、次に、RsAgoを遺伝子発現領域に作用させて、遺伝子発現を調節できるかどうかを確認した(図13)。
(1)精製タンパク質
精製RsAgoタンパク質を作製して用いた。
リン酸化ガイドRNAとしては、以下のものを用いた(上から順に配列番号25~26)。
3’-FAM標識 in vitro合成gRNAアプタマー
(3)標的DNA(T7 pol template)調整
pHMk016を鋳型として、T7プロモーターを含む領域(310bp)をPCRによって増幅した(鋳型について配列番号27、PCR産物について配列番号28)。この増幅産物をFastGene Gel/PCR Extraction Kit(日本ジェネティクス)によって精製した。
反応バッファーとして、80mM HEPES-KOH, pH7.5; 24mM MgCl2; 2mM spermidine; 40mM DTTを用いた。
上記の反応バッファー存在化で精製タンパク質(final 100nM)とガイドRNA(final 4μM)を混合し、25℃で15分間インキュベートして複合体を形成させた。これにPCR産物(標的DNA)を添加し、続いて T7 RNA pol mix (Promega #P1300)およびrNTPs (final 1mM)を添加した。この混合物を37℃で20分間反応させた。この混合物にスクロースを添加した後、1.5%アガロースゲルで電気泳動し、SYBR Goldで染色させた。
(6)結果
図13に示すとおり、完全に閉じた2本鎖DNAにおいては、T7システムを用いて遺伝子発現誘導を行うと、転写に伴って開いたDNAに入り込んで結合し、さらにその遺伝子発現に干渉して正常なmRNA合成を阻害することを確認できた。その効果は特に転写の鋳型とは反対側の鎖へと結合するようにするとより顕著であった。
以上のように、本開示の好ましい実施形態を用いて本開示を例示してきたが、本開示は、特許請求の範囲によってのみその範囲が解釈されるべきであることが理解される。本明細書において引用した特許、特許出願及び他の文献は、その内容自体が具体的に本明細書に記載されているのと同様にその内容が本明細書に対する参考として援用されるべきであることが理解される。本願は、日本国特許庁に2020年12月29日に出願された特願2020-219833に対して優先権主張をするものであり、その内容はその全体があたかも本願の内容を構成するのと同様に参考として援用される。
配列番号2~3:実施例1で用いた合成RNAまたは合成DNA
配列番号4:実施例3で用いた合成RNA
配列番号5~8:実施例3で用いた合成オリゴDNA
配列番号9~12:実施例7で用いた合成DNA
配列番号13~14:実施例4で用いたガイドRNAアプタマー
配列番号15:実施例6で用いた合成RNA
配列番号16:実施例4で用いた鋳型プラスミド
配列番号17~20:実施例6で用いた標的DNA
配列番号21~24:実施例7で用いた標的DNA
配列番号25~26:実施例8で用いたガイドRNAアプタマー
配列番号27:実施例8で用いた鋳型プラスミド
配列番号28:実施例8のPCR産物
Claims (61)
- 標的DNA分子を部位特異的に作用して遺伝子機能を操作するための方法であって、
Argonauteタンパク質とガイドRNAと付加配列とを含む複合体を提供する工程と、
標的DNA分子に、該複合体を接触させる工程と
を含み、該ガイドRNAが、該複合体を標的DNA分子中の目的の部位を含む領域に誘導するように設計される、方法。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項1に記載の方法。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項1または2に記載の方法。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項1~3のいずれか一項に記載の方法。
- 前記Argonauteタンパク質が細菌由来のものである、請求項1~4のいずれか一項に記載の方法。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項1~5のいずれか一項に記載の方法。
- 前記複合体は、生体外で形成される、請求項1~6のいずれか一項に記載の方法。
- 前記複合体は、生体外で形成され、前記標的DNA分子は生体内に存在する、請求項1~7のいずれか一項に記載の方法。
- 前記Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計される、請求項1~8のいずれか一項に記載の方法。
- 前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変および/またはその両方を含む、請求項1~9のいずれか一項に記載の方法。
- 前記遺伝子機能の操作は、遺伝子発現制御を含む、請求項1~9のいずれか一項に記載の方法。
- 前記遺伝子機能の操作は、遺伝子配列改変を含む、請求項1~9のいずれか一項に記載の方法。
- 標的DNA分子の発現を調節するための方法であって、
Argonauteタンパク質とガイドRNAと付加配列とを含む複合体を提供する工程と、
標的DNA分子における二本鎖DNA配列の少なくとも一部を解離させる工程と、
少なくとも一部が解離した二本鎖DNA配列に、該複合体を接触させる工程と
を含み、該ガイドRNAが、該複合体を、少なくとも一部が解離した該二本鎖DNA配列を含む領域に誘導するように設計される、方法。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項13に記載の方法。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項13または14に記載の方法。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項13~15のいずれか一項に記載の方法。
- 前記Argonauteタンパク質が細菌由来のものである、請求項13~16のいずれか一項に記載の方法。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項13~17のいずれか一項に記載の方法。
- 前記複合体は、生体外で形成される、請求項13~18のいずれか一項に記載の方法。
- 前記複合体は、生体外で形成され、前記標的DNA分子は生体内に存在する、請求項13~19のいずれか一項に記載の方法。
- Argonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されている、Argonaute-ガイドRNA複合体。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項21に記載の複合体。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項21または22に記載の複合体。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項21~23のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質が細菌由来のものである、請求項21~24のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項21~25のいずれか一項に記載の複合体。
- 標的DNA分子を部位特異的に作用して遺伝子機能を操作するためのArgonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子に部位特異的に作用して遺伝子機能が操作される、Argonaute-ガイドRNA複合体。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項27に記載の複合体。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項27または28に記載の複合体。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項27~29のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質が細菌由来のものである、請求項27~30のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項27~31のいずれか一項に記載の複合体。
- 前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変、および/またはその両方を含む、請求項27~32のいずれか一項に記載の複合体。
- 前記遺伝子機能の操作は、遺伝子発現制御を含む、請求項27~32のいずれか一項に記載の複合体。
- 前記遺伝子機能の操作は、遺伝子配列改変を含む、請求項27~32のいずれか一項に記載の複合体。
- 標的DNA分子の発現を調節するためのArgonaute-ガイドRNA複合体であって、
Argonauteタンパク質と、
合成されたガイドRNAポリヌクレオチドと
を含み、前記ガイド配列は、Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計されており、該複合体が該標的分子に結合することで該標的DNA分子の発現が調節される、Argonaute-ガイドRNA複合体。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項36に記載の複合体。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項36または37に記載の複合体。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項36~38のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質が細菌由来のものである、請求項36~39のいずれか一項に記載の複合体。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項36~40のいずれか一項に記載の複合体。
- 標的DNA分子を部位特異的に作用して遺伝子機能を操作するためのシステムまたはキットであって、
Argonauteタンパク質、ガイドRNAおよび付加配列、またはこれらのうち2以上を含む2以上の複合体と、
標的DNA分子に、該複合体を接触させる手段または試薬と
を含み、該ガイドRNAが、該複合体を標的DNA分子中の目的の部位を含む領域に誘導するように設計される、システムまたはキット。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項42に記載のシステムまたはキット。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項42または43に記載のシステムまたはキット。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項42~44のいずれか一項に記載のシステムまたはキット。
- 前記Argonauteタンパク質が細菌由来のものである、請求項42~45のいずれか一項に記載のシステムまたはキット。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項42~46のいずれか一項に記載のシステムまたはキット。
- 前記複合体を、生体外で形成するための手段を含む、請求項42~47のいずれか一項に記載のシステムまたはキット。
- 前記複合体を、生体外で形成するための手段を含み、前記標的DNA分子は生体内に存在する、請求項42~48のいずれか一項に記載のシステムまたはキット。
- 前記Argonaute-ガイドRNA複合体が標的近接モチーフ配列を有する標的DNA分子を指向するように設計される、請求項42~49のいずれか一項に記載のシステムまたはキット。
- 前記遺伝子機能の操作は、遺伝子発現制御、遺伝子配列改変および/またはその両方を含む、請求項42~50のいずれか一項に記載のシステムまたはキット。
- 前記遺伝子機能の操作は、遺伝子発現制御を含む、請求項42~50のいずれか一項に記載のシステムまたはキット。
- 前記遺伝子機能の操作は、遺伝子配列改変を含む、請求項42~50のいずれか一項に記載のシステムまたはキット。
- 標的DNA分子の発現を調節するためのシステムまたはキットであって、
Argonauteタンパク質、ガイドRNAおよび付加配列、またはこれらのうち2以上を含む2以上の複合体と、
標的DNA分子における二本鎖DNA配列の少なくとも一部を解離させる手段または試薬と、
少なくとも一部が解離した二本鎖DNA配列に、該複合体を接触させる手段または試薬と
を含み、該ガイドRNAが、該複合体を、少なくとも一部が解離した該二本鎖DNA配列を含む領域に誘導するように設計される、システムまたはキット。 - 前記Argonauteタンパク質がDNAを標的とする活性を有する、請求項54に記載のシステムまたはキット。
- 前記Argonauteタンパク質が生理的な温度においてDNAを標的とする活性を有する、請求項54または55に記載のシステムまたはキット。
- 前記Argonauteタンパク質が原核生物由来のものである、請求項54~56のいずれか一項に記載のシステムまたはキット。
- 前記Argonauteタンパク質が細菌由来のものである、請求項54~57のいずれか一項に記載のシステムまたはキット。
- 前記Argonauteタンパク質がRhodobactor由来のRsAgoである、請求項54~58のいずれか一項に記載のシステムまたはキット。
- 前記複合体を、生体外で形成する手段をさらに含む、請求項54~59のいずれか一項に記載のシステムまたはキット。
- 前記複合体を、生体外で形成する手段をさらに含み、前記標的DNA分子は生体内に存在する、請求項54~60のいずれか一項に記載のシステムまたはキット。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/259,831 US20240093240A1 (en) | 2020-12-29 | 2021-12-28 | Gene function control by novel guide nucleic acid mechanism |
JP2022573114A JPWO2022145465A1 (ja) | 2020-12-29 | 2021-12-28 | |
CN202180087977.XA CN116670156A (zh) | 2020-12-29 | 2021-12-28 | 基于新型指导核酸机制的基因功能调控 |
EP21915323.6A EP4273240A1 (en) | 2020-12-29 | 2021-12-28 | Gene function control by novel guide nucleic acid mechanism |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020219833 | 2020-12-29 | ||
JP2020-219833 | 2020-12-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022145465A1 true WO2022145465A1 (ja) | 2022-07-07 |
Family
ID=82260803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/048908 WO2022145465A1 (ja) | 2020-12-29 | 2021-12-28 | 新規ガイド核酸機構による遺伝子機能制御 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240093240A1 (ja) |
EP (1) | EP4273240A1 (ja) |
JP (1) | JPWO2022145465A1 (ja) |
CN (1) | CN116670156A (ja) |
WO (1) | WO2022145465A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018005873A1 (en) * | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
-
2021
- 2021-12-28 JP JP2022573114A patent/JPWO2022145465A1/ja active Pending
- 2021-12-28 EP EP21915323.6A patent/EP4273240A1/en active Pending
- 2021-12-28 WO PCT/JP2021/048908 patent/WO2022145465A1/ja active Application Filing
- 2021-12-28 US US18/259,831 patent/US20240093240A1/en active Pending
- 2021-12-28 CN CN202180087977.XA patent/CN116670156A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018005873A1 (en) * | 2016-06-29 | 2018-01-04 | The Broad Institute Inc. | Crispr-cas systems having destabilization domain |
Non-Patent Citations (38)
Title |
---|
"GenBank", Database accession no. ABP72561.1 |
"Grace's Insect Medium", NATURE, vol. 195, 1962, pages 788 |
"Journal of Experiments in Molecular Genetics", 1972, COLD SPRING HARBOR LABORATORY, pages: 431 - 433 |
"Molecular Biology", 1990, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE, article "Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in" |
ADAMS, R.L. ET AL., THE BIOCHEMISTRY OF THE NUCLEIC ACIDS, 1992 |
AUSUBEL, F.M.: "Current Protocols in Molecular Biology", 1987, GREENE PUB. ASSOCIATES AND WILEY-INTERSCIENCE |
BESSATSU JIKKEN IGAKU, EXPERIMENTAL MEDICINE, SUPPLEMENTAL VOLUME |
BIO/TECHNOLOGY, vol. 6, 1988, pages 47 - 55 |
BLACKBURN, G.M. ET AL.: "Nucleic Acids in Chemistry and Biology", 1996, OXFORD UNIVERSITY PRESS |
CHAPMANHALLSHABAROVA, Z. ET AL., ADVANCED ORGANIC CHEMISTRY OF NUCLEIC ACIDS, 1994 |
GAIT, M.J.: "Oligonucleotide Synthesis: A Practical Approach", 1990, IRL PRESS |
GENE, vol. 17, 1982, pages 107 |
GENE, vol. 24, 1983, pages 255 |
GENETICS, vol. 39, 1954, pages 440 |
HOCKEMEYER D ET AL., NAT BIOTECHNOL, vol. 27, 2009, pages 851 - 857 |
IDENSHI DONYUHATSUGEN KAISEKIJIKKEN HO, EXPERIMENTAL METHODS FOR TRANSGENESIS & EXPRESSION ANALYSIS |
IN VIVO, vol. 13, 1977, pages 213 - 217 |
INNIS, M.A. ET AL.: "Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", 1999, GREENE PUB. ASSOCIATES |
JOURNAL OF BIOCHEMISTRY, vol. 95, 1984, pages 87 |
JOURNAL OF MOLECULAR BIOLOGY, vol. 120, 1978, pages 517 |
JOURNAL OF MOLECULAR BIOLOGY, vol. 41, 1969, pages 459 |
LISITSKAYA LIDIA; PETUSHKOV IVAN; ESYUNINA DARIA; ARAVIN ALEXEI; KULBACHINSKIY ANDREY: "Recognition of double-stranded DNA by the Rhodobacter sphaeroides Argonaute protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM NL, vol. 533, no. 4, 24 October 2020 (2020-10-24), Amsterdam NL , pages 1484 - 1489, XP086405915, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2020.10.051 * |
LIU YIWEI, ESYUNINA DARIA, OLOVNIKOV IVAN, TEPLOVA MARIANNA, KULBACHINSKIY ANDREY, ARAVIN ALEXEI A., PATEL DINSHAW J.: "Accommodation of Helical Imperfections in Rhodobacter sphaeroides Argonaute Ternary Complexes with Guide RNA and Target DNA", CELL REPORTS, ELSEVIER INC, US, vol. 24, no. 2, 10 July 2018 (2018-07-10), US , pages 453 - 462, XP055948532, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2018.06.021 * |
METHODS IN ENZYMOLOGY, vol. 194, 1991, pages 182 - 187 |
MOLECULAR & GENERAL GENETICS, vol. 168, 1979, pages 111 |
NATURE, vol. 315, 1985, pages 592 |
NUCLEIC ACIDS RESEARCH, vol. 9, 1981, pages 309 |
OCHIAI H, INT J MOL SCI, vol. 16, 2015, pages 21128 - 21137 |
PROC. NATL. ACAD. SCI. USA, vol. 60, 1968, pages 160 |
PROC. NATL. ACAD. SCI. USA, vol. 69, 1972, pages 2110 |
PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 1929 |
PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4505 |
PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5330 |
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1 |
SAMBROOK J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR |
SCIENCE, vol. 122, 1952, pages 501 |
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
VIROLOGY, vol. 8, 1959, pages 396 |
Also Published As
Publication number | Publication date |
---|---|
CN116670156A (zh) | 2023-08-29 |
JPWO2022145465A1 (ja) | 2022-07-07 |
EP4273240A1 (en) | 2023-11-08 |
US20240093240A1 (en) | 2024-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3348636B1 (en) | Method for modifying genome sequence that specifically converts nucleobase of targeted dna sequence, and molecular complex used in said method | |
JP6153180B2 (ja) | 脱塩基反応により標的化したdna配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体 | |
US20130059344A1 (en) | Transcription terminator sequences | |
US20200017852A1 (en) | Compositions and methods for target nucleic acid modification | |
WO2015168404A1 (en) | Toehold-gated guide rna for programmable cas9 circuitry with rna input | |
GB2617658A (en) | Class II, type V CRISPR systems | |
EP2401365A1 (en) | Reengineering mrna primary structure for enhanced protein production | |
EP3447139B1 (en) | Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor | |
Muñoz-Adelantado et al. | Mobility of the Sinorhizobium meliloti group II intron RmInt1 occurs by reverse splicing into DNA, but requires an unknown reverse transcriptase priming mechanism | |
JP7250349B2 (ja) | 細胞の有する二本鎖dnaの標的部位を改変する方法 | |
WO2022145465A1 (ja) | 新規ガイド核酸機構による遺伝子機能制御 | |
US20180291066A1 (en) | In vivo production of long double stranded rna utilizing vlps | |
WO2006130976A1 (en) | Interfering rnas, methods for their production, and use | |
WO2022050413A1 (ja) | 小型化シチジンデアミナーゼを含む二本鎖dnaの改変用複合体 | |
KR101873327B1 (ko) | 애기 장대에서 유래한 신규 호밍 엔도뉴클레아제 | |
Woldrich et al. | Site-directed A-to-I editing to manipulate protein expression | |
AU2020356441A1 (en) | A nucleic acid delivery vector comprising a circular single stranded polynucleotide | |
KR20180083394A (ko) | 게놈 변형을 위한 안정화된 시약 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21915323 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022573114 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180087977.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021915323 Country of ref document: EP Effective date: 20230731 |